Arvee Laboratories (India) Ltd
Incorporated in 2012, Arvee Laboratories India Ltd manufactures specialized chemicals[1]
- Market Cap ₹ 182 Cr.
- Current Price ₹ 165
- High / Low ₹ 233 / 127
- Stock P/E 455
- Book Value ₹ 28.5
- Dividend Yield 0.00 %
- ROCE 10.0 %
- ROE 7.12 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.63 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -3.26% over past five years.
- Company has a low return on equity of 8.58% over last 3 years.
- Earnings include an other income of Rs.0.80 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | 38.49 | 26.29 | |
| 21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.41 | 34.88 | 25.27 | |
| Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 2.94 | 3.61 | 1.02 |
| OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.69% | 9.38% | 3.88% |
| 0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.64 | 0.66 | 0.80 | |
| Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 | 0.25 | 0.20 |
| Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 | 1.15 | 1.14 |
| Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 | 2.87 | 0.48 |
| Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% | 25.09% | |
| 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | 2.15 | 0.40 | |
| EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 | 1.95 | 0.36 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 15% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 | 20.24 | 20.42 |
| 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.03 | 1.03 | |
| 7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.08 | 5.87 | 8.11 | |
| Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
| 13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.67 | 15.27 | 15.25 | |
| CWIP | 4.30 | 0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 | 0.73 | 0.81 |
| Investments | 0.00 | 0.00 | 0.00 | 1.95 | 3.09 | 2.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 22.90 | 22.16 | 24.52 | |
| Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
Cash Flows
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.03 | 6.02 | 9.46 | 10.31 | 1.71 | 0.68 | 2.93 | 3.66 | -0.04 | ||
| -1.40 | -1.23 | -2.85 | -3.08 | -0.60 | 0.06 | -1.26 | -2.16 | -1.39 | ||
| -2.92 | -3.78 | -4.92 | -9.90 | 4.52 | -6.06 | -2.42 | -0.19 | -0.21 | ||
| Net Cash Flow | -0.29 | 1.00 | 1.68 | -2.67 | 5.63 | -5.32 | -0.75 | 1.31 | -1.64 |
Ratios
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 | 79.66 |
| Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 159.02 | 80.31 |
| Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 164.49 | 57.72 |
| Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 | 102.25 |
| Working Capital Days | 30.08 | 30.84 | 30.79 | -6.52 | 10.29 | -10.63 | 49.96 | 70.44 | 95.97 | 106.59 |
| ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% | 10.00% |
Documents
Announcements
-
Outcome of Board Meeting
14 November 2025 - Board-approved unaudited results for half-year ended 30/09/2025: Q2 revenue 368.01 lakh, H1 profit 17.93 lakh.
-
Shareholders meeting
24 September 2025 - 24 Sep 2025 AGM: adopted FY2025 accounts; appointed director Saurin Gandhi; reappointed Neetu Jalan and Praveen Mishra.
-
Trading Window
22 September 2025 - Trading window closed from 1 Oct 2025 until two working days after results for period ended 30 Sep 2025.
-
Shareholders meeting
30 August 2025 - 13th AGM on 24 September 2025; annual report FY2024-25 submitted; director and auditor appointments proposed.
-
Appointment
12 August 2025 - Appointment of Saurin Gandhi as Additional Director and CFO with 4000 shares, effective 12 Aug 2025.
Product Profile:
a) Polymer Modifiers:[1]
Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt, 5-Sodiosulfo-Bis-(β-Hydroxyethyl)-Isophthalate
b) Contrast Media Intermediates:[2]
5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic
acid, 5-Aminoisophthalic acid, Dimethyl
5-Aminoisophthalate, 3,5-Dinitrobenzoic
Acid, 3,5-Diamino Benzoic Acid
c) Drug Intermediates:[3]
2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, Amino Pyridine,
Chloro Nitrobenzoic Acid